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Abstract Phosphatidylinositol 3-kinase (PI 3-K) is a lipid and 
protein kinase which associates with the activated platelet-derived 
growth factor (PDGF) receptor and other tyrosine kinases. We 
studied the effects of wortmannin, a selective inhibitor of PI 3-K, 
on the activation of extracellular-signal regulated kinase (ERK) 
by PDGF in cultured hepatic stellate cells, mesenchymal cells 
responsible for extracellular matrix synthesis within the liver. 
Incubation with 100 nM wortmannin, a dose which almost com- 
pletely blocks PI 3-K, resulted in 50% reduction of ERK activity. 
Direct inhibition of ERK by wortmannin could not be considered 
responsible for this effect, since wortmannin did not inhibit ERK 
activity in vitro. Rather, inhibition of PI 3-K acts on the kinase 
cascade that leads to ERK activation, since PDGF-dependent 
phosphorylation of ERK was found to be reduced after incubation 
with wortmannin. Wortmannin also inhibited the increase in c-los 
mRNA induced by PDGF, which is dependent on ERK activation. 
The results of this study show that in hepatic stellate cells PI 3-K 
is involved in ERK activation, although it is not necessary. These 
data indicate cross-talk between PI 3-K and the Ras/ERK path- 
way in PDGF-stimulated cells. 
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1. Introduction 
Platelet-derived growth factor (PDGF) regulates several cel- 
lular functions, such as mitogenesis, migration, and neoplastic 
transformation. PDGF signals through two tyrosine kinase 
receptors which dimerize and become phosphorylated on tyro- 
sine residues upon binding to their ligand [1]. The phosphoty- 
rosines on the activated receptor function as high-affinity bind- 
ing sites for several molecules involved in downstream trans- 
mission of the signal, which bind through src-homology-2 (SH- 
2) domains or phosphotyrosine-binding omains [2,3]. Associa- 
tion of the PDGF receptor with the adapter protein Grb2 leads 
to recruitment of the exchange factor mSos and subsequent 
activation of Ras [4]. Activated Ras triggers a kinase cascade, 
with sequential activation of Raf-1, MEK and extracellular- 
signal regulated kinase (ERK) [5]. ERK belongs to the family 
of mitogen-activated protein kinases [5]. Two isoforms have 
been identified, and are referred to as ERK-1 (or p44 MARK) and 
ERK-2 (or p42 MAPK) [6]. Upon translocation to the nucleus, 
ERK phosphorylates several transcription factors, including 
Elk-1 and SAP-I [7-9]. Growth factor-mediated activation of 
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ERK has been shown to be an absolute requirement for trigger- 
ing a proliferative response [10]. 
Another molecule which is recruited by the activated PDGF 
receptor is phosphatidylinositol 3-kinase (PI 3-K). This lipid 
and protein kinase is comprised ofa 85-kDa regulatory subunit, 
equipped with two SH-2 domains, and a catalytic 110 kDa 
subunit [11]. PDGF stimulation leads to an association of PI 
3-K with the activated receptor, and to tyrosine phosphoryla- 
tion of p85 but not of pl l0.  The signals generated by PI 3-K 
are only partially known, but this pathway has been shown to 
be sufficient o transduce a PDGF-dependent mitogenic signal 
[12]. Recent data indicate that the Ras/ERK and PI 3-K path- 
ways may interact at different levels. Rodriguez-Viciana et al. 
[13] have reported that PI 3-K is a target of Ras. On the other 
hand, a mutant PDGF receptor that no longer associates with 
PI 3-K does not activate Ras [14], and transfection of a consti- 
tutively active form of PI 3-K results in stimulation of the 
Ras/ERK pathway [15]. These reports uggest that PI 3-K may 
act both downstream and upstream of Ras. However, no stud- 
ies have yet elucidated the contribution of the PI 3-K pathway 
to the activation of ERK by PDGF in non-transformed, non- 
transfected cells. To address this issue, we used wortmannin, 
a selective PI 3-K inhibitor, which allows to study the effects 
of the interruption of the PI 3-K pathway in intact cells [16]. 
The effects of wortmannin on ERK activation in response to 
PDGF were investigated in hepatic stellate cells (HSC). HSC 
are liver-specific pericytes located in the hepatic sinusoid, which 
during liver injury undergo transition to a highly proliferative, 
matrix-producing phenotype and participate in the process of 
liver tissue healing and liver fibrosis [17]. PDGF is the most 
potent mitogen for human HSC in culture, and may be pro- 
duced by HSC themselves, creating an autocrine loop [18]. 
Therefore, these cells represent an optimal system model to 
study the post-receptor effects of PDGF or other cytokines on 
primary cells, and the findings are potentially relevant for the 
pathophysiology of liver diseases. We report that P! 3-K is 
involved in PDGF-dependent activation of ERK, thus showing 
a cross-talk between PI 3-K and the Ras/ERK pathway in 
PDGF-stimulated cells. 
2, Experimental 
2.1. Reagents 
Monoclonal, agarose-conjugated antiphosphotyrosine antibodies 
were purchased by Oncogene Science (Uniondale, NY, USA). Rabbit 
antisera gainst ERK were a kind gift of Dr. M.J. Dunn (Medical 
College of Wisconsin, USA). The antisera recognized both ERK-1 and 
ERK-2. Wortmannin, phosphatidylinositol, and myelin basic protein 
were from Sigma Chemical Co. (St. Louis, MO, USA). Protein A- 
Sepharose was purchased from Pharmacia (Uppsala, Sweden). 
[7-3~-P]ATP (3000 Ci/mmol) and [~-32p]dCTP (3000 Ci/mmol) were from 
New England Nuclear (Milan, Italy). Human recombinant PDGF BB 
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was from Boehringer Mannheim (Mannheim, Germany). All other 
reagents were of analytical grade. 
2.2. Cell culture 
Human liver HSC were isolated from liver tissue unsuitable for trans- 
plantation by collagenase/pronase digestion and centrifugation on 
stractan gradients, as previously described [19]. The cells were grown 
in Iscove's medium in the presence of 17% fetal calf serum. 
2.3. Preparation of cell lysates 
Confluent HSC were serum-starved for 48 h, and treated as indicated 
in section 3. They were then quickly placed on ice and washed with 
ice-cold PBS. The monolayer was lysed in RIPA buffer (20 mM Tris- 
HCI pH 7.4, 150 mM NaCI, 5 mM EDTA, 1% Nonidet P-40, 1 mM 
Na3VO4, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.05% (w/v) 
aprotinin). Insoluble proteins were discarded by high-speed centrifuga- 
tion at 4°C. Protein concentration i  the supernatant was measured in
triplicate using a commercially available assay (BioRad, Hercules, CA). 
2.4. Phosphatidylinositol 3-kinase assay 
PI 3-K assay was performed as described elsewhere [20]. Briefly, the 
cells were lysed in RIPA buffer and identical amounts of protein were 
immunoprecipitated using antiphosphotyrosine antibodies. After 
washing, the immunobeads were resuspended in 50 ~ul of 20 mM Tris- 
HCI pH 7.5, 100 mM NaC1, and 0.5 mM EGTA. 0.5 pl of 20 mg/ml 
phosphatidylinositol was added, and the samples were incubated at 
25°C for 10 min. I pl of l M MgCI 2 and 10/tCi of[7-3Zp]ATP were then 
added simultaneously, and the incubation was continued for 10 more 
minutes. The reaction was stopped by addition of 150 pl of chloroform/ 
methanol/37% HC1 (10:20:0.2). Samples were extracted with chloro- 
form and dried. Radioactive lipids were separated by thin-layer chrom- 
atography, developing with chloroform/methanol/30% ammonium hy- 
droxide/water (46:41 : 5 : 8). After drying, the plates were autoradiogra- 
phed. Identity of the 3-OH phosphorylated lipids after separation by 
thin-layer chromatography as been previously assessed by high-pres- 
sure liquid chromatography [20]. The radioactive spots were then 
scraped and counted. 
2.5. Extracellulat~signal regulated kinase assay 
ERK was measured as the myelin basic protein kinase activity of 
ERK immunoprecipitates. RIPA lysates from HSC (6(L100/zg of pro- 
tein) were immunoprecipitated with rabbit polyclonal anti-ERK anti- 
bodies and protein A-Sepharose. After washing, the immunobeads were 
incubated ina buffer containing 10 mM HEPES pH 7.4, 20 mM MgCI2, 
I mM dithiotreitol, 1mM Na3VO4, 1/zCi [7-32PLATE and 0.5 mg/ml 
myelin basic protein for 30 rain at 30°C. At the end of the incubation, 
15/zl of the reaction were spotted onto phosphocellulose disks, washed 
four times in 1% phosphoric acid, and the radioactivity counted in a 
beta-counter. Another aliquot (10 ,ul) of the reaction mixture was run 
on 15% SDS-PAGE [21]. After electrophoresis, the gel was dried and 
autoradiographed 
2.6. Western blotting 
Identical amounts of protein were separated by SDS-PAGE accord- 
ing to Laemmli [21], and electroblotted ona polyvinylidene-difluoride 
membrane. The membranes were blocked overnight at 4°C with 2% 
bovine serum albumin in 0.1% PBS-Tween, and sequentially incubated 
at room temperature with rabbit anti-ERK antibodies and then horse- 
radish peroxidase-conjugated anti-rabbit antibody (Gibco-BRL, 
Grand Island, NY, USA). Detection was carried out using chemilumi- 
nescence according to the manufacturer's protocol (Amersham, Arling- 
ton Heights, IL, USA). 
2. 7. Northern blot analysis 
RNA was isolated according to Chomczynski and Sacchi [22]. Ten 
pg of total RNA were fractionated by 1% agarose-formaldehyde gel 
electrophoresis, and blotted on a nylon membrane. Procedures for 
DNA labeling and filter hybridization have been described in detail 
elsewhere [23]. Autoradiographic signals have been quantitated using 
a densitometer (BioRad, Hercules, CA, USA). 
3. Results and discussion 
We first tested the ability of wortmannin of blocking PDGF-  
E Marra et aZ/FEBS Letters 376 (1995) 141-145 
PDGF - - + + 
WT - + - + 
i 
1 2 3 4 
P I3K  act iv i ty  (cpm)  
1 ,000r  
800 
600  
400 
200 
0 
1 2 3 4 
Fig. 1. Wortmannin blocks activation of PI 3-K by PDGF. Serum- 
starved HSC were incubated with 100 nM wortmannin (WT; lanes 2 
and 4) or vehicle (dimethyl sulfoxide, lanes 1 and 3) for 30 min before 
addition of PDGF (10 ng/ml, lanes 3 and 4) for 10 min. Cell lysates were 
immunoprecipitated with antiphosphotyrosine antibodies and PI 3-K 
assay was carried out as described in section 2. The upper panel shows 
autoradiography of [32p]phosphatidylinositol-3-phosphate. The radio- 
active spots were scraped and counted in a beta-counter, asshown in 
the lower panel. 
stimulated PI 3-K activity. Little PI 3-K activity was detectable 
in unstimulated, serum-starved HSC (Fig. 1). Incubation with 
PDGF (10 ng/ml) dramatically increased the PI 3-K activity 
associated with phosphotyrosine immunoprecipitates (Fig. 1, 
lane 3). Pretreatment of HSC with 100 nM wortmannin, re- 
sulted in nearly total inhibition of this activity (Fig. 1, lanes 3 
and 4). Exposure of HSC to PDGF also stimulated ERK activ- 
ity, which was increased 5 min following addition of the ag- 
onist, peaked at 10-15 min and persisted for at least 30 min 
(data not shown). Fig. 2A illustrates the effects of wortmannin 
on PDGF-stimulated ERK activity. Incubation with the PI 3-K 
inhibitor resulted in 50% inhibition of ERK activity (Fig. 2A, 
compare lanes 3 and 4). This incomplete inhibition was consist- 
ently observed in different experiments. However, a lower sen- 
sitivity of ERK to wortmannin cannot be considered responsi- 
ble for this incomplete ffect since doses as high as 0.5/.tM 
wortmannin resulted in an identical degree of inhibition (data 
not shown). Doses in the micromolar range were not used since 
they are no longer specific for PI 3-K [24]. Wortmannin did not 
affect ERK activity in unstimulated HSC (Fig. 2A, lane 2). 
Although the effects ofwortmannin at nanomolar concentra- 
tions are presumed to be specific for PI 3-K, a direct effect on 
ERK cannot be ruled out. Therefore, we studied whether wort- 
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Fig. 2. Wortmannin hibits ERK activation i  vivo but not in vitro. (A) Serum-starved HSC were incubated exactly as described in Fig. 1. Cell lysates 
were immunoprecipitated with polyclonal anti-ERK antibodies, and the immunobeads were assayed for myelin basic protein kinase activity as 
described in section 2. The upper panel shows phosphorylated myelin basic protein after running on 15% SDS-PAGE. The lower panel shows counts 
after spotting the reaction mix on phosphocellulose discs and extensive washing. (B) Serum-starved HSC were incubated with 10 mg/ml PDGF (lanes 
2 and 3). Cell lysates were immunoprecipitated with polyclonal nti-ERK antibodies. The immunobeads were assayed for ERK activity after addition 
ofwortmannin (final concentration 100 nM, lane 3) or its vehicle (dimethyl sufoxide, lanes 1 and 2). ERK assay was carried out as described in Fig. 2A. 
The small stimulatory effect in samples treated with wortmannin was not reproducible. 
mannin is an inhibitor of ERK in vitro. HSC were incubated 
with PDGF and ERK assay was carried out after addition of 
100 nM wortmannin or its vehicle (dimethyl sulfoxide) to the 
immunobeads (Fig. 2B). No differences in ERK activity were 
observed in the presence or absence of wortmannin (Fig. 2B). 
These data indicate that wortmannin does not exert a direct 
inhibitory effect on ERK, but that rather it blocks the pathways 
leading to its activation. Activation of ERK is regulated via 
phosphorylation through a cascade of different protein kinases, 
which constitute the so-called Ras/ERK pathway [5]. Stimula- 
tion with different growth factors, including PDGF, results in 
activation of Ras, which recruits the serine/threonine kinase 
Raf-1 to the plasma membrane, where it becomes active [25]. 
Raf-1 phosphorylates and activates a dual specificity kinase 
(ERK kinase, or MEK), which phosphorylates ERK on tyro- 
sine and threonine residues [26,27]. Therefore, we investigated 
whether the observed inhibition of ERK by wortmannin was 
dependent on an effect on ERK phosphorylation. Exposure of 
HSC to PDGF resulted in a slower electrophoretic mobility of 
ERK-1 and ERK-2, indicating phosphorylation of tyrosine 
and/or threonine residues (Fig. 3, lanes 1 and 2). In the presence 
of wortmannin, the amount of protein shifted upward was 
reduced, indicating reduced phosphorylation of both ERK 
isoforms (compare lane 2 and lane 3). As observed with the 
kinase assay (Fig. 2B), the inhibitory effect by wortmannin on 
ERK phosphorylation was incomplete, and this occurred even 
when higher doses (0.5 ¢tM) were employed (data not shown). 
Together, these data indicate that PI 3-K acts on the kinase 
cascade responsible for ERK activation. 
In mammalian cells, the Ras/ERK pathway directs signals to 
the serum response lement of the promoter of c-fos and other 
coregulated genes. Targets for ERK activity include the ternary 
complex factor (TCF) proteins Elk-I and SAP-I [8,28]. A TCF 
Table 1 
Quantitative analysis of PDGF-induced c-fos expression i  the presence 
or absence of wortmannin (data from Fig. 4) 
Control PDGF 30 min PDGF 60 min 
Wortmannin - - + - + 
0 4.25 2.96 0.49 0.08 
Data are the ratio of c-fos/36B4 mRNA abundance as measured by 
densitometry (arbitrary units). 
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protein binds to the serum response lement along with the 
serum response factor and mediate increased gene expression 
[29]. We evaluated the effects of wortmannin on PDGF-in- 
duced increase in c-jos expression, as a target of ERK activa- 
tion. The abundance ofc-fos mRNA was increased 30 rain after 
addition of PDGF and declined thereafter (Fig. 4). Pretreat- 
ment of HSC with wortmannin resulted in reduced c-fos expres- 
sion at both time points (31% inhibition at 30 rain, see Table 
1), indicating inhibition of the nuclear phase of the Ras/ERK 
pathway. It is worth noticing that also in this case wortmannin 
reduced, but did not abolish, the increase in c-fos expression. 
Growth factor-dependent signals are important for several 
disease states, such as hepatic or renal fibrosis, atherosclerosis 
or cancer. PDGF is a potent mitogen for HSC, and its expres- 
sion is increased uring liver injury [30]. PDGF activates PI 
3-K, but the signal transduction pathways that originate from 
activation of this enzyme have only partially been clarified. PI 
3-K regulates several cellular functions, including mitosis, cell 
migration, and programmed cell death [12,31,32]. Protein ki- 
nase C( [33], ribosomal $6 kinase [34], and the protooncogene 
c-Akt [35] have been indicated as downstream targets of the PI 
3-K pathway. Data presented in this paper indicate that in 
non-transformed, non-transfected cells PI 3-K activation par- 
ticipates in PDGF-mediated activation of ERK. However, 
ERK activation appears to occur via both PI 3-K-dependent 
and independent pathways. In fact, a dose of wortmannin that 
virtually blocks PI 3-K, resulted in only 50% reduction of ERK 
activity in PDGF-stimulated cells. These observations are in 
keeping with data showing that activation of the Ras/ERK 
pathway occurs through Grb2/mSos [4]. According to the pres- 
ent study, concomitant activation of PI 3-K would lead to a 
greater activation of ERK, most likely acting at the level of Ras 
[15]. PI 3-K activation has been shown to be involved in 
PDGF's mitogenic signaling [12]. Preliminary data from our 
laboratory show that inhibition of PI 3-K using wortmannin 
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Fig. 3. Wortmannin inhibits ERK phosphorylation. Serum-starved 
HSC were incubated with 100 nM wortmannin (WT; lane 3) or vehicle 
(dimethyl sulfoxide, lanes 1 and 2) for 30 min before addition of PDGF 
(10 ng/ml, lanes 2 and 3) for l0 min. Twenty ~tg of cell lysate were 
separated by 12% SDS-PAGE and blotted with polyclonal anti-ERK 
antibodies. Bands corresponding to phosphorylated ERK are indicated 
by an asterisk (*). 
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Fig. 4. Wortmannin inhibits PDGF-induced expression of c-fos 
mRNA. Serum-starved HSC were incubated with 100 nM wortmannin 
(WT) or vehicle (dimethyl sulfoxide) for 30 rain before addition of 
PDGF (10 ng/ml) for the indicated time points. Ten ~g of total RNA 
were separated on an agarose-formaldehyde gel, blotted an a membrane 
and hybridized with radiolabeled probes encoding for c-los and for the 
ribosomal protein 36B4 (control gene). 
completely blocks DNA synthesis in response to PDGF [36]. 
Since the inhibition of ERK activation by wortmannin s only 
partial, data from this study indicate that the mitogenic signal 
of PI 3-K follows ERK-dependent and independent pathways. 
Tyrosine kinase receptors activate an array of different sig- 
naling pathways. Although they may be thought of as inde- 
pendent avenues leading to separate ffects, accumulating evi- 
dence, including the data from this study, indicates cross-talk 
at different levels. Proliferation of HSC is a growth-factor reg- 
ulated event, which is implicated in the deterioration of liver 
function during chronic disease [17]. A better understanding of 
the mechanisms that regulate the function of these ffector cells 
will aid in the development of new strategies for the treatment 
of liver diseases. 
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